{"name":"River 3 Renal Corp.","slug":"river-3-renal-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOdEhIV3lPamJHbFNhMmFsZTJHXzRMTGtHZUs0dV9lRTVQV0VDQmUwVEdDc0hReDZzcDVmLS1ONTRZa2dYWWR6R0V0dW9kd0xkQl9Da3d4T3lDZU9nSFNYTi1KV1MzWTc4WFpPbFJzby0zdDVMenV0dnZoejZDaXZxcGo5LTBpUFFQRVlRMEZXRlBtOENVV1ppSmlZTmYwQldsQUZSSzJWeWFrcW5oeUp3ZkZmanlzZmxKVWlVSWV2WElpNGV3THNfM0xDaW1yM3oteFFEdDVtREVZaElvZE9LR0JhaTkzTi1sVnpCc1hlaW5seXZ1V1FFRW4tQVRMN1NUbzVqU3doYlJjNG1MUm5EaDJ3TDJtLTNqWmNuNzBWZXVMUE16Nzl5STBCWQ?oc=5","date":"2026-04-06","type":"pipeline","source":"GlobeNewswire","summary":"Idiopathic Membranous Nephropathy Market is Predicted to - GlobeNewswire","headline":"Idiopathic Membranous Nephropathy Market is Predicted to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNS0tkVHd1V3U0RVFORTZ5MVJNbXR5dGZ0Vi01YUYxcS1TYjZDSnYwQ2RoT2ZWbjVCRk9ldlBvTmMzZHVmOUtOM2VQRE40SWZ2bTlKZExMOVE0dHpSRWRKZmJ3Z05oQlpuM0pUUE1UTnFIYVFTZFJMYXlzQWprMzgycFp0ZFRMSlFWOE9SNQ?oc=5","date":"2025-10-24","type":"pipeline","source":"Yahoo Finance","summary":"Why Apellis Pharmaceuticals (APLS) Could Gain from EMPAVELI’s Edge in Rare Kidney Disease Treatment - Yahoo Finance","headline":"Why Apellis Pharmaceuticals (APLS) Could Gain from EMPAVELI’s Edge in Rare Kidney Disease Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE9xd25ZWjJ3cEwxZlRFM21CcVI5bzFRZVBQNWh2WGRMaDVHZTFqZmlUSU9wcG9sMlNRMmx4TWZPeTVuZkhwcnVyMjg0QURWV19LYzN3VkdYWHgwUUhVNWtzUHRKS2c0dw?oc=5","date":"2024-05-17","type":"pipeline","source":"MedPage Today","summary":"Sparsentan Bests Irbesartan for Rare, Progressive Kidney Disease - MedPage Today","headline":"Sparsentan Bests Irbesartan for Rare, Progressive Kidney Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOTXM3aU1PZ3hRZU9XQ1gtUjVhRjVyNmJReDJwS0tmMGRlbEdiN0ZLYVEtZDdYYUdYMW54N0tJRTZGZy1rSjBlLTN1NGpLQXlHUVFnVUxLTU85ZF9lclJsQTkycXdGbHV1UFdZLVpVTzJTZjJNMkNYNmVjN1V5bjI3X2F5X015aWpxNVdDZUZPVHhEbmstbTJFSVlidDJlOGt2SHJJWUJCYXlQcHhuRWxtb0JTU1JNdjA0NUcwVHROU25KNHdnLVJsMXFGMUEzVnpPdnJRa0pNNWtReXdZSlZnWGFPVzN0aktW?oc=5","date":"2024-04-17","type":"pipeline","source":"PR Newswire","summary":"Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight - PR Newswire","headline":"Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-10","type":"pipeline","source":"PR Newswire","summary":"Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelhei","headline":"Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companie","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}